World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
71
Citations
20370
World Ranking
2298
National Ranking
29

Pierre van der Bruggen publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Pierre van der Bruggen sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 202 publications — 35th percentile

35% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Pierre van der Bruggen D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Pierre van der Bruggen sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 71 D-Index — 54th percentile

54% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Pierre van der Bruggen is affiliated with Université Catholique de Louvain in Belgium and specializes in research at the intersection of immunology, microbiology, and medicine. Their scholarly work primarily focuses on immune cells in cancer and immunotherapy, targeting mechanisms involving immune cell function and interaction as well as galectins and cancer biology.

Their main research fields include:

  • Immunology and Microbiology
  • Medicine

Van der Bruggen's subfields of study encompass:

  • Immunology
  • Oncology
  • Molecular Biology
  • Radiology, Nuclear Medicine and Imaging
  • Cell Biology

Key topics covered in their research are:

  • Immune cells in cancer
  • Immune Cell Function and Interaction
  • Galectins and Cancer Biology
  • Immunotherapy and Immune Responses
  • Immune Response and Inflammation
  • CAR-T cell therapy research
  • T-cell and B-cell Immunology

They have contributed to several peer-reviewed papers including:

  • "Endophilin-A3 and Galectin-8 control the clathrin-independent endocytosis of CD166," 2020, published in Nature Communications
  • "A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability," 2020, Cancer Research
  • "MDSC in Mice and Men: Mechanisms of Immunosuppression in Cancer," 2021, Journal of Clinical Medicine
  • "Identification of an Immature Subset of PMN-MDSC Correlated to Response to Checkpoint Inhibitor Therapy in Patients with Metastatic Melanoma," 2021, Cancers
  • "Immunosuppressive low-density neutrophils in the blood of cancer patients display a mature phenotype," 2023, Life Science Alliance

Frequent collaborators include:

  • Thibault Hirsch
  • Christophe Vanhaver
  • Alexandre Bayard
  • Annika M. Bruger
  • Mathieu Luyckx

Van der Bruggen's research has been disseminated in various scientific journals, with repeated publications in venues such as Nature Communications, Cancer Research, Journal of Clinical Medicine, Life Science Alliance, and Cell Reports.

Best Publications

  • Tumor-antigens recognized by T-lymphocytes

    Thierry Boon;Jean-Charles Cerottini;Benoît Van den Eynde;Pierre van der Bruggen

  • Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

    Pierre G. Coulie;Benoît J. Van den Eynde;Pierre van der Bruggen;Thierry Boon

  • Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

    M Marchand;N van Baren;N van Baren;P Weynants;P Weynants;V Brichard;V Brichard;V Brichard

  • Structure, Chromosomal Localization, and Expression of 12 Genes of the Mage Family

    Etienne De Plaen;Etienne De Plaen;Catia Traversari;Catia Traversari;José J.J. Gaforio;José J.J. Gaforio;Jean Pierre Szikora;Jean Pierre Szikora

  • HUMAN T CELL RESPONSES AGAINST MELANOMA

    Thierry Boon;Pierre G Coulie;Benoît J Van den Eynde;Pierre van der Bruggen

  • T cell defined tumor antigens

    Benoît J Van den Eynde;Pierre van der Bruggen

  • Bage - a New Gene Encoding An Antigen Recognized On Human Melanomas By Cytolytic T-lymphocytes

    Pascale Boël;Claude Wildmann;Maria Luisa Sensi;Robert Brasseur

  • Tumor-specific shared antigenic peptides recognized by human T cells

    Pierre van der Bruggen;Yi Zhang;Pascal Chaux;Vincent Stroobant

  • A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.

    P van der Bruggen;J Bastin;T Gajewski;T Gajewski;P G Coulie

  • A CASP-8 Mutation Recognized by Cytolytic T Lymphocytes on a Human Head and Neck Carcinoma

    Susanna Mandruzzato;Francis Brasseur;Guy Andry;Thierry Boon

  • An Antigenic Peptide Produced by Peptide Splicing in the Proteasome

    Nathalie Vigneron;Vincent Stroobant;Jacques Chapiro;Annie Ooms

  • Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes

    Pascal Chaux;Valérie Vantomme;Vincent Stroobant;Kris Thielemans

  • Autologous Human Monocyte-Derived Dendritic Cells Genetically Modified to Express Melanoma Antigens Elicit Primary Cytotoxic T Cell Responses In Vitro: Enhancement by Cotransfection of Genes Encoding the Th1-Biasing Cytokines IL-12 and IFN-α

    Thomas Tüting;Cara C. Wilson;Dina M. Martin;Yvette L. Kasamon

  • Genes coding for tumor-antigens recognized by cytolytic T-lymphocytes

    Aline Van Pel;Pierre Van Der Bruggen;Pierre G. Coulie;Vincent G. Brichard

  • Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601

    Pierre Van Der Bruggen;Jean Pierre Szikora;Pascale Boël;Claude Wildmann

  • Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.

    Yong Chen Lu;Linda L. Parker;Tangying Lu;Zhili Zheng

  • Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules.

    Aude Bonehill;Carlo Heirman;Sandra Tuyaerts;Annelies Michiels

  • Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients

    Aude Bonehill;An M.T. Van Nuffel;Jurgen Corthals;Sandra Tuyaerts

  • Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes.

    Nathalie Demotte;Nathalie Demotte;Vincent Stroobant;Vincent Stroobant;Pierre J. Courtoy;Patrick Van Der Smissen

  • Database of T cell-defined human tumor antigens: the 2013 update.

    Nathalie Vigneron;Vincent Stroobant;Vincent Stroobant;Benoît J. Van den Eynde;Benoît J. Van den Eynde;Pierre van der Bruggen;Pierre van der Bruggen

  • Characterization of the GAGE genes that are expressed in various human cancers and in normal testis.

    Olivier De Backer;Karen C. Arden;Mauro Boretti;Valérie Vantomme

  • Human Gene MAGE-3 Codes for an Antigen Recognized on a Melanoma by Autologous Cytolytic T Lymphocytes By Btatrice Gaugler,* Benoit Van den Eynde,*

    Pierre van der Bruggen;Pedro Romero;Jose Juan Gaforio;Etienne De Plaen

Frequent Co-Authors

Thierry Boon
Thierry Boon Ludwig Cancer Research
Benoît Van den Eynde
Benoît Van den Eynde Ludwig Cancer Research
Pierre Coulie
Pierre Coulie Université Catholique de Louvain
Vincent Stroobant
Vincent Stroobant Ludwig Cancer Research
Kris Thielemans
Kris Thielemans Vrije Universiteit Brussel
Francis Brasseur
Francis Brasseur Ludwig Cancer Research
Catia Traversari
Catia Traversari MolMed (Italy)
Carlo Heirman
Carlo Heirman Vrije Universiteit Brussel
Jean-Christophe Renauld
Jean-Christophe Renauld Université Catholique de Louvain
Gerold Schuler
Gerold Schuler University of Erlangen-Nuremberg

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Immunology as a field opens doors to various healthcare careers, many of which can be pursued through online education. For those with a nursing background looking to advance, accelerated RN to NP programs offer a fast track from registered nurse to nurse practitioner roles, emphasizing patient care and immunological health.

Beginners interested in healthcare but without prior experience may find online nursing programs for non nurses particularly accessible. These programs provide foundational nursing knowledge, essential for understanding immunological principles in clinical settings.

For students aiming to enter nursing quickly, ABSN programs with high acceptance rates can be a practical choice, offering accelerated paths into nursing that complement immunology studies.

Additionally, those seeking a nursing role with less stringent admission demands might consider LPN programs with easiest admission requirements. These programs enable quick entry into practical nursing, where immunology knowledge is valuable for patient care.

Best Scientists Citing Pierre van der Bruggen

Trending Scientists